Cooley-Led Oncology Firm Prices $94M IPO Below Range
Oncology firm Acrivon Therapeutics Inc. rose in debut trading Tuesday after completing an upsized $94 million initial public offering, albeit at a lower price than expected, represented by Cooley LLP and...To view the full article, register now.
Already a subscriber? Click here to view full article